All News

acupuncture

Efficacy of Acupuncture for Sciatica

MedPage Today

Real Chinese acupuncture was more effective than a sham version for treating sciatica stemming from herniated spinal disks in a randomized trial conducted in China.

Read Article
RheumNow Podcast square

Dot the "i", Cross the "t" (10.11.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.

Read Article
artificial intelligence machine learning computer

Artificial Intelligence in Diagnosing Sacroiliac Inflammation in axSpA

MedPage Today

A so-called deep learning artificial intelligence (AI) algorithm for analyzing MRI scans showed "acceptable" agreement with expert human readers for detecting sacroiliac joint (SIJ) inflammation in patients with axial spondyloarthritis (axSpA), researchers said.

Read Article
RheumNow Podcast square

Stop Counting Bugs (10.4.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.

Read Article
uveitis.3.jpg

Risk of Uveitis with Spondyloarthritis

Jack Cush, MD

A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can significantly lower the risk of uveitis in (SpA).

Read Article
xray%20spine%20films_0.jpg

ASAS Imaging Recommendations for Suspected Spondyloarthritis

Jack Cush, MD

ASAS (Assessment of Spondyloarthritis International Society) has convened specialized task force to guide imaging request on patients with suspected/known axial spondyloarthritis (axSpA).

Read Article
Upadacitinib safety across in RA, PsA, AS, atopic dermatitis >15000 Pt-Yrs exposure. Rates (per 100PYs) of Hzoster (1.6–3.6), NMSC (0–0.8) & incr CPK (4.4–7.9) higher w/ UPA vs comparators (RA, PsA); Deaths (0–0.8), SIE (0–3.9), MACE (0–0.4), VTE (<0.1–0.4), CA, malignancies… https://t.co/OoJ5OX7JyL https://t.co/vaMVFmldEB
Dr. John Cush RheumNow ( View Tweet)
Risk of Uveitis with Spondyloarthritis A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can… https://t.co/96rRu77Tyl https://t.co/bGHnZ7lCIm
Dr. John Cush RheumNow ( View Tweet)
World renowned faculty delivering state of the art lectures. Early bird registration for RheumNow Live is now open! https://t.co/Yk8dKDdZie https://t.co/d14Mq2AxlI

Links:

Dr. John Cush RheumNow ( View Tweet)
Artificial Intelligence in Diagnosing Sacroiliac Inflammation in axSpA A so-called deep learning artificial intelligence (AI) algorithm for analyzing MRI scans showed "acceptable" agreement with expert human readers for detecting sacroiliac joint (SIJ) inflammation in patients… https://t.co/nKbYF603ut https://t.co/Y5IzVIG2l3
Dr. John Cush RheumNow ( View Tweet)
Analgesic Prescribing in Patients with Inflammatory Arthritis A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis (IA) patients has declined, but still remains substantial, including opioid… https://t.co/K43YERU3rf https://t.co/DRZ4r9JDSv
Dr. John Cush RheumNow ( View Tweet)
Korean Claims analysis of 413 radiographic axial spondyloarthritis (TNFi exposed=75 ). Recurrent CV events = 32 per 1,000 person-years; but lower if TNFi Rx'd = 19/1000PYs. TNFi exposure significantly lowered risk of recurrent CV events https://t.co/f69SHpXZCx https://t.co/ofpg0JbrR1

Links:

Dr. John Cush RheumNow ( View Tweet)
ASAS Imaging Recommendations for Suspected Spondyloarthritis ASAS (Assessment of Spondyloarthritis International Society) has convened specialized task force to guide imaging request on patients with suspected/known axial spondyloarthritis (axSpA). https://t.co/snSKDtToHh https://t.co/wpGSHkTwCD

Links:

Dr. John Cush RheumNow ( View Tweet)
Taiwan claims data study compared (2003-2013) 30,911 newly diagnosed #AS pts to 309,110 controls found significantly higher risk of motor vehicle accidents w/ injuries in AS, esp. 2yrs after Dx (IRR 2.0) https://t.co/Ca0LN675oj https://t.co/UKQMgQYMAL

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wvZYVbVW83 https://t.co/n26xAeU64s

Links:

Dr. John Cush RheumNow ( View Tweet)
Which One is the Loneliest Number (9.27.2024) Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer… https://t.co/c4YKKXbweX https://t.co/pEaA5qVvd9
Dr. John Cush RheumNow ( View Tweet)
Pooled data from #PsA (n=914) & #AS (n=372) RCTs looked at outcomes in smokers (37% & 48%). Current or past smoking had NO EFFECT on outcomes (MDA, ACR50, ASAS40, ASDAS), but incr odds of D/C & some SAE (SIE) but not MACE, HZ, VTE https://t.co/WRflSVO3Ig https://t.co/YMI5YCT0QK

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 866 #AS pts shows those w/ lower socioeconomic status (SES) had longer Dx delay, higher BME, more structural damage, & permanent disability (31% vs 13%), compared to high SES AS pts; despite similar use of bDMARDs betw groups. https://t.co/x0dfFACUz9 https://t.co/tOmhE9vGiH

Links:

Dr. John Cush RheumNow ( View Tweet)
Diagnostic delay of 7.4 yrs (median 4yrs) in axSpA. An Int’l IMAS cross-sectional online Pt. survey (2017–22) 5,557 axSpA pts (27 countries). The highest delay in S Africa & lowest in Asia. Longer Dx delay assoc w/ younger age, female, rheumatologist Dx, # HCPs, & Hx uveitis… https://t.co/sqf2uamKG6 https://t.co/JUseWzbwUh
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory… https://t.co/aITAeYuJxv https://t.co/tAPFfshPSs
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×